Spots Global Cancer Trial Database for stage iiib breast cancer ajcc v7

Every month we try and update this database with for stage iiib breast cancer ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC	NCT02593175	Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative...	Carboplatin Paclitaxel Panitumumab	18 Years -	M.D. Anderson Cancer Center
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC	NCT02593175	Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative...	Carboplatin Paclitaxel Panitumumab	18 Years -	M.D. Anderson Cancer Center
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer	NCT02474173	Advanced Breast... Metastatic Brea... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Triple-Negative...	Laboratory Biom... Onalespib Paclitaxel Pharmacological...	18 Years -	National Cancer Institute (NCI)
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes	NCT02079662	Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Behavioral, Psy... Best Practice Cognitive Inter... Computer-Assist... Counseling Exercise Interv... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer	NCT01142401	Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Bortezomib Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence	NCT04054557	Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage III Breas...	Telemedicine Best Practice Questionnaire A... Quality-of-Life... Survey Administ... Behavioral Inte... Educational Int...	18 Years -	Thomas Jefferson University
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	NCT03106415	Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Binimetinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	NCT01463072	Locally Advance... Metastatic Brea... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Nab-paclitaxel Questionnaire A...	65 Years -	City of Hope Medical Center
SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer	NCT03411070	Positive Axilla... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Implanted Medic... Therapeutic Con...	18 Years -	Jonsson Comprehensive Cancer Center
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer	NCT00684983	HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer	NCT00376688	Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative	NCT02276443	Invasive Breast... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative...	Chemotherapy Immunotherapy Laboratory Biom... Lymph Node Biop... Ultrasonography	18 Years -	M.D. Anderson Cancer Center
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery	NCT03317405	Breast Ductal C... Breast Lobular ... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Endoxifen Hydro... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	NCT03428802	BRCA1 Gene Muta... BRCA2 Gene Muta... Locally Advance... Metastatic Mali... POLD1 Gene Muta... POLE Gene Mutat... Recurrent Malig... Recurrent Ovari... Stage III Breas... Stage III Ovari... Stage IIIA Brea... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Laboratory Biom... Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer	NCT02689427	Invasive Breast... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative...	Axillary Lymph ... Enzalutamide Laboratory Biom... Lymph Node Biop... Paclitaxel Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC	NCT02593175	Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative...	Carboplatin Paclitaxel Panitumumab	18 Years -	M.D. Anderson Cancer Center
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer	NCT01351909	Locally Advance... Metastatic Brea... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Cyclophosphamid... Laboratory Biom... Veliparib	18 Years -	National Cancer Institute (NCI)
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer	NCT03012100	Bilateral Breas... Breast Inflamma... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative... Unilateral Brea...	Cyclophosphamid... Laboratory Biom... Multi-epitope F... Placebo Adminis... Sargramostim	18 Years -	Academic and Community Cancer Research United
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)	NCT00310180	Breast Adenocar... Hormone Recepto... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIB Brea...	Anastrozole Exemestane Laboratory Biom... Letrozole Quality-of-Life... Radiation Thera... Tamoxifen Citra...	18 Years - 75 Years	National Cancer Institute (NCI)
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer	NCT00684983	HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer	NCT01142401	Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Bortezomib Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	NCT01463072	Locally Advance... Metastatic Brea... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Nab-paclitaxel Questionnaire A...	65 Years -	City of Hope Medical Center
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes	NCT02079662	Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Behavioral, Psy... Best Practice Cognitive Inter... Computer-Assist... Counseling Exercise Interv... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)	NCT00310180	Breast Adenocar... Hormone Recepto... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIB Brea...	Anastrozole Exemestane Laboratory Biom... Letrozole Quality-of-Life... Radiation Thera... Tamoxifen Citra...	18 Years - 75 Years	National Cancer Institute (NCI)
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	NCT03106415	Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Binimetinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer	NCT03101748	Breast Inflamma... Locally Advance... Metastatic Brea... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Cyclophosphamid... Doxorubicin Laboratory Biom... Neratinib Paclitaxel Pertuzumab Trastuzumab	18 Years -	M.D. Anderson Cancer Center
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative	NCT02276443	Invasive Breast... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative...	Chemotherapy Immunotherapy Laboratory Biom... Lymph Node Biop... Ultrasonography	18 Years -	M.D. Anderson Cancer Center
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery	NCT00770809	Male Breast Car... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Laboratory Biom... Lapatinib Ditos... Paclitaxel Trastuzumab	18 Years -	National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer	NCT01142401	Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Bortezomib Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	NCT01463072	Locally Advance... Metastatic Brea... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Nab-paclitaxel Questionnaire A...	65 Years -	City of Hope Medical Center
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer	NCT02003209	HER2-Positive B... Hormone Recepto... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Aromatase Inhib... Carboplatin Cytology Specim... Docetaxel Goserelin Aceta... Laboratory Biom... Pertuzumab Quality-of-Life... Therapeutic Con... Trastuzumab Whole Breast Ir...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: